Glenmark Pharma ties up with Seqirus

Glenmark Pharmaceuticals ties up with Seqirus (Seqirus), part of Australia-based specialty biotechnology company CSL by an exclusive licensing agreement to commercialize Ryaltris in Australia and New Zealand. Ryaltris (olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)) is a novel, investigational, fixed-dose combination nasal spray of an antihistamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age. Under the terms of the agreement, Glenmark will be responsible for product supply and Seqirus will be responsible for regulatory filing and commercialization of the product in Australia and New Zealand.

Company Profile : Glenmark Pharma Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*